Venlafaxine treatment stimulates blood platelet activity [9]

Journal of Clinical Psychopharmacology

Volumn 20, Issue 5, 2000, Pages 589-590

  Tharmapathy, Pasupathy ^a,c   Selheim, Frode ^a   Ødegaard, Ketil ^b,c   Lund, Anders ^b,c   Holmsen, Holm ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN; GLYCOPROTEIN; ISOTHIOCYANIC ACID; MUSCARINIC RECEPTOR; PHOSPHATIDYLINOSITIDE; PHYCOERYTHRIN; VENLAFAXINE;

ACUTE HEART INFARCTION; ANTICOAGULATION; DEPRESSION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG RELEASE; LETTER; PRIORITY JOURNAL; RECEPTOR AFFINITY; THROMBOCYTE AGGREGATION; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PLATELETS; CYCLOHEXANOLS; FLOW CYTOMETRY; HUMANS; P-SELECTIN; PLATELET ADHESIVENESS;

EID: 0033825722     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200010000-00023     Document Type: Letter

References (8)

1. In vitro antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881
2. 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: Synthesis and antidepressant activity
3. Binding of antidepressants to human brain receptors: Focus on newer generation compounds
4. Venlafaxine: A review of its pharmacology and therapeutic potential in depression
5. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry
6. Elevation of cyclic AMP decreases phosphoinositide turnover and inhibits thrombin-induced secretion in human platelets
7. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881
8. Biochemical, neurophysiological, and behavioral effects of Wy45,233 and other identified metabolites of the antidepressant venlafaxine